These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22446485

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S.
    Clin Cancer Res; 2007 Jul 15; 13(14):4280-90. PubMed ID: 17634558
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
    Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P.
    Clin Cancer Res; 2008 Sep 01; 14(17):5385-99. PubMed ID: 18765530
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
    Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P.
    Cancer Biol Ther; 2009 Nov 01; 8(21):2084-96. PubMed ID: 19823038
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):893-905. PubMed ID: 21487100
    [Abstract] [Full Text] [Related]

  • 31. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
    Samuel S, Tumilasci VF, Oliere S, Nguyên TL, Shamy A, Bell J, Hiscott J.
    Mol Ther; 2010 Dec 08; 18(12):2094-103. PubMed ID: 20842105
    [Abstract] [Full Text] [Related]

  • 32. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 33. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C.
    Leukemia; 2014 Sep 15; 28(9):1861-71. PubMed ID: 24561519
    [Abstract] [Full Text] [Related]

  • 34. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
    Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.
    Blood; 2014 Oct 23; 124(17):2687-97. PubMed ID: 25208888
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM.
    J Biol Chem; 2011 Mar 18; 286(11):9382-92. PubMed ID: 21148306
    [Abstract] [Full Text] [Related]

  • 38. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC.
    Proc Natl Acad Sci U S A; 2007 Dec 04; 104(49):19512-7. PubMed ID: 18040043
    [Abstract] [Full Text] [Related]

  • 39. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 04; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.